tradingkey.logo


Viatris Inc

VTRS

8.905USD

+0.095+1.08%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
10.56BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Viatris Inc āļšāļĢāļīāļĐāļąāļ—
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VTRS
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Viatris Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 1973
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Scott A. Smith
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™32000
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Feb 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ1000 Mylan Boulevard
āđ€āļĄāļ·āļ­āļ‡CANONSBURG
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Select Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ15317
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ17245141465
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.viatris.com/en
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VTRS
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 1973
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Scott A. Smith
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
+13.74%
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--
Ms. Theodora (Doretta) Mistras
Ms. Theodora (Doretta) Mistras
Chief Financial Officer
Chief Financial Officer
25.18K
--
Ms. JoEllen Lyons Dillon
Ms. JoEllen Lyons Dillon
Independent Director
Independent Director
--
--
Mr. Mark W. Parrish
Mr. Mark W. Parrish
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Melina E. Higgins
Ms. Melina E. Higgins
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
+13.74%
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Brands
2.12B
65.27%
Generics
1.13B
34.73%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Developed markets
1.90B
58.54%
Greater China
555.50M
17.13%
Emerging Markets
523.10M
16.13%
JANZ
277.10M
8.54%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Brands
2.12B
65.27%
Generics
1.13B
34.73%
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
12.27%
T. Rowe Price Associates, Inc.
6.19%
Davis Selected Advisers, L.P.
5.53%
BlackRock Institutional Trust Company, N.A.
5.48%
State Street Global Advisors (US)
5.24%
Other
65.29%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
12.27%
T. Rowe Price Associates, Inc.
6.19%
Davis Selected Advisers, L.P.
5.53%
BlackRock Institutional Trust Company, N.A.
5.48%
State Street Global Advisors (US)
5.24%
Other
65.29%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
44.92%
Investment Advisor/Hedge Fund
26.24%
Hedge Fund
6.57%
Pension Fund
2.59%
Research Firm
2.39%
Bank and Trust
1.26%
Sovereign Wealth Fund
1.06%
Individual Investor
0.26%
Family Office
0.06%
Other
14.65%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
1937
999.77M
85.18%
-69.44M
2025Q1
2006
1.01B
85.93%
-61.76M
2024Q4
2002
1.03B
86.53%
+1.20M
2024Q3
1949
989.28M
82.89%
-66.19M
2024Q2
1967
1.02B
85.33%
-16.59M
2024Q1
1986
997.86M
84.00%
-35.39M
2023Q4
2032
990.53M
82.57%
-31.15M
2023Q3
2044
970.48M
80.90%
-45.34M
2023Q2
2080
963.51M
80.35%
-35.04M
2023Q1
2188
941.77M
78.68%
-93.71M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
144.00M
12.27%
+2.51M
+1.77%
Mar 31, 2025
T. Rowe Price Associates, Inc.
72.68M
6.19%
+15.75M
+27.67%
Mar 31, 2025
Davis Selected Advisers, L.P.
64.95M
5.53%
+2.37M
+3.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
64.32M
5.48%
+1.23M
+1.95%
Mar 31, 2025
State Street Global Advisors (US)
61.46M
5.24%
-2.29M
-3.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
31.17M
2.66%
+1.11M
+3.68%
Mar 31, 2025
Deerfield Management Company, L.P.
23.99M
2.04%
-4.44K
-0.02%
Mar 31, 2025
Invesco Capital Management LLC
23.22M
1.98%
-2.85M
-10.95%
Mar 31, 2025
Columbia Threadneedle Investments (US)
21.60M
1.84%
+677.90K
+3.24%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
21.26M
1.81%
+5.84M
+37.90%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
iShares U.S. Pharmaceuticals ETF
4.58%
First Trust NASDAQ Pharmaceuticals ETF
3.9%
SPDR S&P Pharmaceuticals ETF
3.81%
Franklin US Dividend Multiplier Index ETF
3.03%
Invesco Pharmaceuticals ETF
2.81%
Davis Select US Equity ETF
2.73%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.7%
Invesco S&P Ultra Dividend Revenue ETF
2.53%
Leatherback Long/Short Alternative Yield ETF
2.47%
Hennessy Sustainable ETF
2.24%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.58%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.9%
SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.81%
Franklin US Dividend Multiplier Index ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.03%
Invesco Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.81%
Davis Select US Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.73%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.7%
Invesco S&P Ultra Dividend Revenue ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.53%
Leatherback Long/Short Alternative Yield ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.47%
Hennessy Sustainable ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.24%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 2.13B USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
Feb 27, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 18, 2025
Mar 10, 2025
Nov 05, 2024
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 13, 2024 going ex on Nov 22, 2024
Nov 22, 2024
Dec 13, 2024
Nov 22, 2024
Aug 06, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 13, 2024 going ex on Aug 23, 2024
Aug 23, 2024
Sep 13, 2024
Aug 23, 2024
May 09, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 14, 2024 going ex on May 23, 2024
May 24, 2024
Jun 14, 2024
May 23, 2024
Feb 28, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2024 going ex on Mar 08, 2024
Mar 11, 2024
Mar 18, 2024
Mar 08, 2024
Nov 08, 2023
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 15, 2023 going ex on Nov 22, 2023
Nov 24, 2023
Dec 15, 2023
Nov 22, 2023
Aug 07, 2023
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 15, 2023 going ex on Aug 23, 2023
Aug 24, 2023
Sep 15, 2023
Aug 23, 2023
May 08, 2023
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 16, 2023 going ex on May 23, 2023
May 24, 2023
Jun 16, 2023
May 23, 2023
Feb 27, 2023
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 17, 2023 going ex on Mar 08, 2023
Mar 09, 2023
Mar 17, 2023
Mar 08, 2023
Nov 08, 2022
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 16, 2022 going ex on Nov 22, 2022
Nov 23, 2022
Dec 16, 2022
Nov 22, 2022
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™